# PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

> **NCT03685591** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 49 (actual)

## Conditions studied

- Breast Neoplasms
- Prostate Neoplasms
- Neoplasms, Squamous Cell
- Melanoma
- Mesothelioma
- Pancreatic Neoplasms
- Colorectal Neoplasms
- Carcinoma, Renal Cell
- Liver Neoplasms

## Interventions

- **DRUG:** PF-06952229
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03685591
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-04
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** The decision to stop enrollment was due to strategic considerations and not due to any specific safety reasons or request from a regulatory authority.
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685591, "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03685591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*